Printed From BioPortfolio.com
Pfizer makes $830m drug discovery pact with Arvinas
05:15 EST 4 Jan 2018 | Pharmafile
Arvinas has managed to secure another big pharma collaboration, after it announced that Pfizer had signed a research and licensing agreement. The deal adds to previous agreements signed with MSD and Genentech, cementing pharma’s interest in the biotech’s research area.
The biotech works on developing drug candidates that are designed to degrade disease-causing cellular proteins, rather than the more common method of inhibiting certain proteins. The potential candidates are discovered through Arvinas’ proprietary PROTAC (PROteolysis TArgeting Chimeras) Platform.
Original Article: Pfizer makes $830m drug discovery pact with Arvinas
